Biobetters Market - Growth, Trends, and Forecast(2022 - 2027)

The Biobetters market is segmented by Drug Class (Erythropoeitin Biobetters, Insulin Biobetters, G- CSF Biobetters, Monoclonal Antibodies Biobetters, Anti-Haemophlic factor and Other Biological Drug Biobetters), Application, Route of Administration, Distribution Channel and Geography

Biobetters Market Snapshot

Biobetter Market Summary
Study Period: 2017-2025
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Biobetters market studied is expected to grow with an anticipated CAGR of 7.8%, during the forecast period. With the developments in biotechnology, advances are being made in the treatment of most of the diseases. One such most important advent is Biobetters. The major drivers of the Biobetters market are the advantages of Biobetters such as superior therapeutic efficacy, lower adverse effects, easier and less costly manufacturing processes, non-patent and market exclusivity, longer product half-life, less dosing frequency and availability of high investment opportunities in this sector. By the year 2020, approximately USD 110 billion worth of biopharmaceuticals are expected to be off patent and almost one third of the pharmaceutical sector is comprised of biopharmaceuticals.

A biobetter can be assigned a premium price for its improved characteristics, compared to other similar biologics. However, due to reduction in the number of dosages required, significant cost savings can be achieved. Hence, this impacts the willingness of payers to purchase the product. One such example is Neulasta- a Biobetter of Amgen Inc, to its own drug Neupogen. A single treatment cycle of Neupogen costs USD 6000, whereas Neulasta is USD 3400, though the per unit price of Neupogen is USD 300 and Neulasta is USD 3400. Hence, there is a 40% reduction in the overall cost to the healthcare provider.

Development of Biobetters is also followed as a defense strategy by the originator companies, to protect their market niche against biosimilars and also to overcome patent issues. For example, the subcutaneous formulation of Roche’s trastuzumab was released into market in 2013, before Roche’s Herceptin (intravenous trastuzumab) patent expired in 2014. Hence, the Biobetters Market is estimated to grow rapidly during the forecast period.

Scope of the Report

Biobetters, also known as biosuperiors, are recombinant protein drug from the same class of an existing biopharmaceutical, however not identical and are superior to the original. It is not completely a new drug and also not the generic version of an existing drug. It is a biological product developed with an intention to improve the clinical efficacy, enhancing tolerability and reducing the dosing/administration frequency. Biobetters are the upgraded versions of the existing biologics.

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Insulin Biobetters are Expected to Evident a Prominent Growth over the Forecast Period in Drug Class Segment

As per the CDC, more than 100 million adults in the United States are living with diabetes and prediabetes. According to the International Diabetes Federation, 463 million people are living with diabetes across the globe in 2019 and is expected to increase to 578 million by 2030. The health expenditures for diabetes is expected to rise from USD 760 billion in 2019 to USD 825 billion in 2030. Also, the increasing geriatric population and adoption to various lifestyle has been leading to an increase in the diabetic population. Due to the higher prevalence of diabetes during the forecast period, the segment of insulin biobetters is expected to show a huge market growth across the globe.

Biobetters Marker- Insulin Segmentation

North America is Expected to be a Prominent Biobetters Market over the Forecast Period

As Biobetters are approved through Biologics Approval pathway as new molecules, a 10-12 years of market exclusivity is provided in regions such as North America. This time period allows the originator companies to invest on Research and development. The United States is the global leader in the Biopharmaceutical market, accounting for one-third of the global market. According to the Pharmaceutical Research and Manufacturers Association, over half of the world’s R&D in pharmaceuticals ( USD 75 billion) and Intellectual Property Rights of most new medicines are held by the United States. Also, most of the biopharmaceuticals in the US are getting into collaborations and partnerships with the regional players and investing funds in research and development. For example, Kadcyla drug developed by Roche, approved in 2019 is an adjuvant treatment for HER2- positive early breast cancer in patients affected by residual invasive disease post neoadjuvant taxane-trastuzumab-based treatment.

Biobetters Market_Geography trend.png

Competitive Landscape

The Biobetters market is highly competitive and consists of significant major players, that dominate the market. The major players in Biobetters market are Amgen Inc., Novo Nordisk A/S, L. Hoffmann-La Roche AG, Merck & Co., Inc., Sanofi, Genentech, USA Inc., Eli- Lilly and Company, Biogen Inc., CSL Behring and Pfizer Inc. Most of these companies are involved in strategies such as investing in research and development, acquisitions and collaborations.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Superior Therapeutic Efficacy and Lower Adverse Effects

      2. 4.2.2 Comparatively Easier and Less Costly Manufacturing Processes

      3. 4.2.3 Non- Patent and Market Exclusivity

      4. 4.2.4 Longer product Half-life and Less Dosing Frequency

      5. 4.2.5 High Investment Opportunities

    3. 4.3 Market Restraints

      1. 4.3.1 High Investment in Research and Development

      2. 4.3.2 Increasing Biosimilar Competition

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Class

      1. 5.1.1 Erythropoietin Biobetters

      2. 5.1.2 Insulin Biobetters

      3. 5.1.3 G-CSF Bioreactors

      4. 5.1.4 Monoclonal Antibodies Biobetters

      5. 5.1.5 Anti-Haemophilic Factor

      6. 5.1.6 Other Biological Drug Biobetters

    2. 5.2 By Application

      1. 5.2.1 Cancer

      2. 5.2.2 Diabetes

      3. 5.2.3 Renal Disease

      4. 5.2.4 Neurodegenerative Disease

      5. 5.2.5 Genetic Disorders

      6. 5.2.6 Others

    3. 5.3 By Route of Administration

      1. 5.3.1 Subcutaneous

      2. 5.3.2 Oral

      3. 5.3.3 Inhaled

      4. 5.3.4 Intravenous

      5. 5.3.5 Others

    4. 5.4 By Distribution Channel

      1. 5.4.1 Hospital Pharmacies

      2. 5.4.2 Retail Pharmacies

      3. 5.4.3 Online Pharmacies

    5. 5.5 Geography

      1. 5.5.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.5.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.5.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.5.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.5.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 Novo Nordisk A/S

      3. 6.1.3 L. Hoffmann-La Roche AG

      4. 6.1.4 Merck & Co. ,Inc.

      5. 6.1.5 Sanofi

      6. 6.1.6 Genentech, USA Inc.

      7. 6.1.7 Eli Lilly and Company

      8. 6.1.8 Biogen Inc.

      9. 6.1.9 CSL Behring

      10. 6.1.10 Pfizer Inc


You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Biobetters Market market is studied from 2017 - 2025.

The Biobetters Market is growing at a CAGR of 7.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2019.

Amgen Inc., Novo Nordisk A/s, F.Hoffmann-La Roche AG, Merck & Co., Inc., Biogen Inc. are the major companies operating in Biobetters Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!